Hormone Receptor Status Does Not Affect the Clinical Benefit of Trastuzumab Therapy for Patients with Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Hormone Receptor Status Does Not Affect the Clinical Benefit of Trastuzumab Therapy for Patients with Metastatic Breast Cancer

Published:2005-08 Issue:3 Volume:6 Page:247-252
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Brufsky Adam,Lembersky Barry,Schiffman Kathy,Lieberman Grazyna,Paton Virginia E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference52 articles.

1. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study;Bianco;Lancet,1988

2. Nonparametric estimation from incomplete observation;Kaplan;J Am Stat Assoc,1958

3. Patients with ER+/HER2+ or ER-/HER2 tumors derive similar clinical benefit from trastuzumab (H)-based therapy for metastatic breast cancer;Klein;Proc Am Soc Clin Oncol,2003

4. Prognostic and predictive factors in breast cancer by immunohistochemical analysis;Allred;Mod Pathol,1998

5. Changing role of the oestrogen receptor in the life and death of breast cancer cells;Jordan;Breast,2003

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?;Current Treatment Options in Oncology;2023-07-10

2. THE HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL PROFILE OF MALIGNANT BREAST TUMORS IN NORTH-EAST ROMANIA;Revista Medico-Chirurgicala;2023-03-31

3. Clinical Efficacy of Trastuzumab, Pertuzumab and Docetaxel as First-Line Treatment for Metastatic Triple-Positive Breast Cancer;Advances in Clinical Medicine;2022

4. The Use of Immunotherapy to Treat Metastatic Breast Cancer;Current Medicinal Chemistry;2019-05-13

5. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients;Pharmacoepidemiology and Drug Safety;2019-03-12